Hyperactivation of members of the Src family kinases (SFKs) in CML [13] led to the development of second generation TKIs targeting BCR::ABL1 and SFKs. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.